| Name | Lewis Drug #9 |
|---|---|
| Organization Name | Lewis Drugs Inc |
| Location | 115 N Splitrock Blvd, Brandon, South Dakota 57005 |
| Type | Pharmacy |
| Phone | (605) 367-2910 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
In the battle on Capitol Hill over federal spending cuts, one targeted group poses a particular quandary for Republicans and Democrats alike: working-age military veterans.
A new analysis has found that, among patients with cancer, rates of health insurance coverage vary by patient demographics and by cancer type. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that the expansion of coverage through the Affordable Care Act may disproportionally benefit certain patient populations.
Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.
News outlets analyzed the current political climate as the Senate Finance Committee prepares for a Tuesday vote on health overhaul legislation.
GNC Acquisition Holdings Inc. announced that, in connection with its previously announced initial public offering, the underwriters have exercised in full their option to purchase from the selling stockholders an additional 3.375 million shares of Class A common stock.
› Verified 7 days ago
| NPI Number | 1700975323 |
| Organization Name | LEWIS DRUGS, INC. |
| Doing Business As | LEWIS DRUG #9 |
| Type | Pharmacy |
| Address | 115 N Splitrock Blvd, Brandon, SD 57005 |
| Phone Number | 605-367-2910 |
News Archive
In the battle on Capitol Hill over federal spending cuts, one targeted group poses a particular quandary for Republicans and Democrats alike: working-age military veterans.
A new analysis has found that, among patients with cancer, rates of health insurance coverage vary by patient demographics and by cancer type. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that the expansion of coverage through the Affordable Care Act may disproportionally benefit certain patient populations.
Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.
News outlets analyzed the current political climate as the Senate Finance Committee prepares for a Tuesday vote on health overhaul legislation.
GNC Acquisition Holdings Inc. announced that, in connection with its previously announced initial public offering, the underwriters have exercised in full their option to purchase from the selling stockholders an additional 3.375 million shares of Class A common stock.
› Verified 7 days ago
News Archive
In the battle on Capitol Hill over federal spending cuts, one targeted group poses a particular quandary for Republicans and Democrats alike: working-age military veterans.
A new analysis has found that, among patients with cancer, rates of health insurance coverage vary by patient demographics and by cancer type. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that the expansion of coverage through the Affordable Care Act may disproportionally benefit certain patient populations.
Avila Therapeutics™, Inc., a biotechnology company developing novel covalent drugs that treat diseases through protein silencing, presented results of preclinical studies on its highly selective, small molecule Hepatitis C Virus (HCV) protease inhibitor, AVL-181. Avila showed that AVL-181 promoted complete viral clearance in vitro when used at clinically-relevant concentrations in combination with other HCV therapies.
News outlets analyzed the current political climate as the Senate Finance Committee prepares for a Tuesday vote on health overhaul legislation.
GNC Acquisition Holdings Inc. announced that, in connection with its previously announced initial public offering, the underwriters have exercised in full their option to purchase from the selling stockholders an additional 3.375 million shares of Class A common stock.
› Verified 7 days ago
Lewis Drug #9 Type: Pharmacy Location: 115 N Splitrock Blvd, Brandon, South Dakota 57005 Phone: (605) 367-2910 |